Back to Agenda
Session 7, Track A: Opportunities and Challenges of Electronic Labelling Implementation
Session Chair(s)
Tharany Ganesh, MSc
Head, Regulatory Affairs
AstraZeneca Canada Inc., Canada
Neerja Goyal, MS
Director, Regulatory Strategy and Policy
GlaxoSmithKline, Inc., Canada
Companies and regulatory agencies are implementing new processes to enable patients to have electronic access to the most current patient information. There are many benefits but also challenges in this approach to patients, manufacturers and supply chain partners. This session will explore the benefits and challenges of moving to electronic labelling, summarize global and Canadian efforts in adopting this new patient-centric approach and learnings from pilots conducted to date.
Learning Objective : At the conclusion of this session, participants should be able to:- Describe the benefits and challenges of implementing electronic patient medication information (ePMIs)
- Understand the status of implementation of ePMIs in Canada and globally
Speaker(s)
Stakeholder Supported ePMI Proposal for Canada
Kristin Willemsen, MS
Canadian Generic Pharmaceutical Association, Canada
Vice President, Scientific and Regulatory Affairs
Going Digital: Transitioning to Electronic Product Information
Dag Jordbru, MPharm
NOMA, Norway
Strategic Director, Regulatory Affairs and Better Use of Medicines
Planetary Health, Pharmacy and Paper-Less Monographs
Ariane Blanc, PharmD, MBA, MS, RPh
The Children's Hospital of Eastern Ontario - Ottawa Children's Treatment Centre, Canada
Director of Pharmacy, Chief Clinical Pharmacist
Have an account?